Management of Noncardiac Comorbidities in Chronic Heart Failure

Cardiovascular Therapeutics

Volumn 33, Issue 5, 2015, Pages 300-315

  Chong, Vun Heng ^a   Singh, Jagdeep ^b   Parry, Helen ^a   Saunders, Jocelyn ^c   Chowdhury, Farhad ^c   Mancini, Donna M ^d   Lang, Chim C ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Comorbidities; Drug treatment; Heart failure; Management

Indexed keywords

ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROPOIETIN; ETANERCEPT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INFLIXIMAB; IRON; IRON SACCHARATE; METFORMIN; METOPROLOL SUCCINATE; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SAXAGLIPTIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VILDAGLIPTIN;

ADAPTIVE SERVO VENTILATION; ANEMIA; ARTHRITIS; ARTIFICIAL VENTILATION; ATRIAL OVERDRIVE PACING; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; EXERCISE; HEART ARRHYTHMIA; HEART ATRIUM PACING; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART PROTECTION; HEART REHABILITATION; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NOCTURNAL NASAL CONTINUOUS POSITIVE AIRWAY; OBESITY; OBSTRUCTIVE AIRWAY DISEASE; OXYGEN THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; POLYPHARMACY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING; SURVIVAL PREDICTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; COGNITION DISORDERS; DISEASE COURSE; KIDNEY DISEASES; RESPIRATORY TRACT DISEASES; RISK FACTOR;

ANEMIA; ARTHRITIS; COGNITION DISORDERS; DEPRESSION; DIABETES MELLITUS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; KIDNEY DISEASES; OBESITY; POLYPHARMACY; RESPIRATORY TRACT DISEASES; RISK FACTORS;

EID: 84941195009     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12141     Document Type: Review

References (214)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015;131:e29-e322.
2. Heindenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circ Heart Fail 2013;6:606-619.
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
4. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010: The global burden of disease 2010 study. Circulation 2014;129:1493-1501.
5. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011;124:136-143.
6. Ahluwalia Sangeeta C, Gross CP, Chaudhury SI, Leo-Summers L, Van Ness PH, Fried TR. Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med 2011;26:1145-1151.
7. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59:998-1005.
8. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-2925.
9. Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998;19:1063-1069.
10. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: Results from the National Heart Failure project. Am Heart J 2002;143:412-417.
11. Whellan DJ, Greiner MA, Schulman KA, Curtis LH. Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. Circ Cardiovasc Qual Outcomes 2010;3:33-40.
12. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226-1233.
13. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 2009;11:292-298.
14. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-1894.
15. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-139.
16. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease. 2014.
17. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJ. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: A randomised controlled trial. Eur J Heart Fail 2009;11:684-690.
18. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: A randomized crossover trial. J Am Coll Cardiol 2010;55:1780-1787.
19. Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail 2005;7:640-649.
20. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: A randomised trial. Respir Med 2011;105(Suppl 1):S44-S49.
21. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002;137:715.
22. Mainguy V, Girard D, Maltais F, et al. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol 2012;110:258-263.
23. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-984.
24. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
25. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
26. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964.
27. Kallergis EM, Manios EG, Kanoupakis EM, Schiza SE, Mavrakis HE, Klapsinos NK, Vardas PE. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest 2005;127:2057.
28. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: Part 2: Reassessment in the larger Quebec cohort. Chest 2012;142:305-311.
29. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: A meta-analysis. Chest 2004;125:2309.
30. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ, Morganroth J. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): Occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol. Medicine (Baltimore) 2008;87:319.
31. Donohue JF, Hanania NA, Fogarty C, Campbell SC, Rinehart M, Denis-Mize K. Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2008;2:199.
32. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011;13:885-891.
33. Cormican LJ, Williams A. Sleep disordered breathing and its treatment in congestive heart failure. Heart 2005;91:1265-1270.
34. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
35. Javaheri S, Shukla R, Zeigler H, Wexler L. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol 2007;49:2028-2034.
36. Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011;57:119-127.
37. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: The sleep heart health study. Circulation 2010;122:352-360.
38. Padeletti M, Green P, Mooney AM, Basner RC, Mancini DM. Sleep disordered breathing in patients with acutely decompensated heart failure. Sleep Med 2009;10:353-360.
39. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009;373:82-93.
40. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003;348:1233-1241.
41. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361-366.
42. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353:2025-2033.
43. Egea CJ, Aizpuru F, Pinto JA, et al. Cardiac function after CPAP therapy in patients with chronic heart failure and sleep apnea: A multicenter study. Sleep Med 2008;9:660-666.
44. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
45. Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000;102:61-66.
46. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353:2025-2033.
47. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: A post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007;115:3173-3180.
48. Teschler H, Dohring J, Wang YM, Berthon-Jones M. Adaptive pressure support servo-ventilation: A novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001;164:614-619.
49. Kasai T, Usui Y, Yoshioka T, et al. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 2010;3:140-148.
50. Krachman SL, D'Alonzo GE, Berger TJ, Eisen HJ. Comparison of oxygen therapy with nasal continuous positive airway pressure on Cheyne-Stokes respiration during sleep in congestive heart failure. Chest 1999;116:1550-1557.
51. Sasayama S, Izumi T, Matsuzaki M, et al. Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea. Circ J 2009;73:1255-1262.
52. Mak S, Azevedo ER, Liu PP, Newton GE. Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure. Chest 2001;120:467.
53. Haque WA, Boehmer J, Clemson BS, Leuenberger UA, Silber DH, Sinoway LI. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. J Am Coll Cardiol 1996;27:353-357.
54. Mak S, Egri Z, Tanna G, Colman R, Newton GE. Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation. Am J Physiol Heart Circ Physiol 2002;282:H2414.
55. Javaheri S, Parker TJ, Wexler L, Liming JD, Lindower P, Roselle GA. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996;335:562-567.
56. Garrigue S, Bordier P, Jais P, et al. Benefit of atrial pacing in sleep apnea syndrome. N Engl J Med 2002;346:404-412.
57. Luthje L, Renner B, Kessels R, et al. Cardiac resynchronization therapy and atrial overdrive pacing for the treatment of central sleep apnoea. Eur J Heart Fail 2009;11:273-280.
58. Oldenberg O, Faber L, Vogt J, Dorszewski A, Szabados F, Horstkotte D, Lamp B. Influence of cardiac resynchronisation therapy on different types of sleep disordered breathing. Eur J Heart Fail 2007;9:820-826.
59. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305.
60. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: Body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55-61.
61. Pocock SJ, McMurray JJ, Dobson J, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:2641-2650.
62. Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627-636.
63. Clark AL, Chyu J, Horwich TB. The obesity paradox in men versus women with systolic heart failure. Am J Cardiol 2012;110:77-82.
64. Zamora E, Lupón J, de Antonio M, et al. The obesity paradox in heart failure: Is etiology a key factor? Int J Cardiol 2013;166:601-605.
65. Adamopoulos C, Meyer P, Desai RV, et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: A propensity-matched study. Eur J Heart Fail 2011;13:200-206.
66. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90.
67. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N. The obesity paradox in men with coronary heart disease and heart failure: The role of muscle mass and leptin. Int J Cardiol 2014;171:49-55.
68. Takiguchi M, Yoshihisa A, Miura S, et al. Impact of body mass index on mortality in heart failure patients. Eur J Clin Invest 2014;44:1197-1205.
69. Nagarajan V, Cauthen CA, Starling RC, Tang WH. Prognosis of morbid obesity patients with advanced heart failure. Congest Heart Fail 2013;19:160-164.
70. Rozentryt P, von Haehling S, Lainscak M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: A randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 2010;1:35-42.
71. Vest AR, Young JB. Should we target obesity in advanced heart failure? Curr Treat Options Cardiovasc Med 2014;16:284.
72. Alpert MA, Nusair MB, Mukerji R, et al. Effect of weight loss on ventricular repolarisation in normotensive severely obese patients with and without heart failure. Am J Med Sci 2015;349:17-23.
73. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S. Effects of weight loss on myocardial energetics and diastolic function in obesity. Int J Cardiovasc Imaging 2013;29:1043-1050.
74. Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007;154:277.
75. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:1377-1385.
76. De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004;25:656-662.
77. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017.
78. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974;34:29.
79. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668.
80. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213.
81. Halon DA, Merdler A, Flugelman MY, Rennert HS, Weisz G, Shahla J, Lewis BS. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol 2000;85:1420.
82. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial. Eur Heart J 2010;31:824-831.
83. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011;11:115-128.
84. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-2778.
85. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;111:583.
86. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49:1696.
87. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009;373:2125.
88. MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: A nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010;33:1213-1218.
89. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34, 000 patients. Circ Heart Fail 2013;6:395.
90. Monami M, et al. Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomised clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-697.
91. Scirica BM, Dicembrini I, Mannucci E. Heart failure, saxagliptin and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomised trial. Circulation 2014;130:1579-1588.
92. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: A population-based retrospective cohort study. JACC Heart Fail 2014;2:573-582.
93. Kim J, Samson SL. Cardiovascular effects of incretin therapy in diabetes care. Metab Syndr Relat Disord 2014;12:303-310.
94. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529.
95. Moyé LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE Study: Subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994;15(Suppl B):2.
96. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490.
97. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004;292:2227-2236.
98. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6, 427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-1592.
99. Damman K, Masson S, Hillege HL, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail 2013;1:417-424.
100. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014;35:455-469.
101. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: Insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268.
102. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005;293:572-580.
103. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003;290:2581-2587.
104. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: The ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol 2010;55:872-878.
105. Philbin EF, Santella RN, Rocco TA Jr. Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. J Am Geriatr Soc 1999;47:302-308.
106. Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 2011;4:685-691.
107. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009;120:1577.
108. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265.
109. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469-479.
110. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 2003;41:1438-1444.
111. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551.
112. Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 2010;33:850.
113. Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 2008;14:539.
114. Katz SD. Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail 2004;10:243-247.
115. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-827.
116. Tang YD, Katz SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-2461.
117. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888-891.
118. O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113:986-994.
119. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
120. Androne AS, Katz SD, Lund L, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226-229.
121. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299.
122. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
123. Drueke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
124. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-535.
125. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-801.
126. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-1219.
127. Gonzalez-Costello J, Comin-Colet J. Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial. Eur J Heart Fail 2010;12:1159-1162.
128. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013;165:575-582.
129. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic heart failure. J Card Fail 2011;17:899-906.
130. Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicentre European study. Int J Cardiol 2014;174:268-275.
131. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-112.
132. Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
133. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-668.
134. Almeida OP, Flicker L. The mind of a failing heart: A systematic review of the association between congestive heart failure and cognitive functioning. Intern Med J 2001;31:290-295.
135. Gure TR, Blaum CS, Giordani B, et al. Prevalence of cognitive impairment in older adults with heart failure. J Am Geriatr Soc 2012;60:1724-1729.
136. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: A population-based cohort study. Arch Intern Med 2006;166:1003-1008.
137. Rusanen M, Kivipelto M, Levälahti E, Laatikainen T, Tuomilehto J, Soininen H, Ngandu T. Heart diseases and long-term risk of dementia and Alzheimer's disease: A population-based CAIDE study. J Alzheimers Dis 2014;42:183-191.
138. Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI. Cognitive impairment in older adults with heart failure: Prevalence, documentation, and impact on outcomes. Am J Med 2013;126:120-126.
139. Vogels RL, Oosterman JM, van Harten B, et al. Neuroimaging and correlates of cognitive function among patients with heart failure. Dement Geriatr Cogn Disord 2007;24:418-423.
140. Alosco ML, Brickman AM, Spitznagel MB, et al. Reduced gray matter volume is associated with poorer instrumental activities of daily living performance in heart failure. J Cardiovasc Nurs 2014; doi: 10.1097/JCN.0000000000000218.
141. Kumar R, Woo MA, Macey PM, Fonarow GC, Hamilton MA, Harper RM. Brain axonal and myelin evaluation in heart failure. J Neurol Sci 2011;307:106-113.
142. Vogels RL, van der Flier WM, van Harten B, Gouw AA, Scheltens P, Schroeder-Tanka JM, Weinstein HC. Brain magnetic resonance imaging abnormalities in patients with heart failure. Eur J Heart Fail 2007;9:1003-1009.
143. Choi BR, Kim JS, Yang YJ, et al. Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2006;97:1365-1369.
144. Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag 2012;8:599-611.
145. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 2008;5:126-132.
146. Cohen MB, Mather PJ. A review of the association between congestive heart failure and cognitive impairment. Am J Geriatr Cardiol 2007;16:171-174.
147. Alosco ML, Spitznagel MB, Sweet LH, Josephson R, Hughes J, Gunstad J. Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure. Pacing Clin Electrophysiol 2015;38:178-186.
148. Hjelm C, Strömberg A, Arestedt K, Broström A. Association between sleep-disordered breathing, sleep-wake pattern, and cognitive impairment among patients with chronic heart failure. Eur J Heart Fail 2013;15:496-504.
149. Alosco ML, Spitznagel MB, Gunstad J. Obesity as a risk factor for poor neurocognitive outcomes in older adults with heart failure. Heart Fail Rev 2014;19:403-411.
150. Alosco ML, Spitznagel MB, Josephson R, Hughes J, Gunstad J. COPD is associated with cognitive dysfunction and poor physical fitness in heart failure. Heart Lung 2015;44:21-26.
151. Alosco ML, Spitznagel MB, Raz N, et al. The interactive effects of cerebral perfusion and depression on cognitive function in older adults with heart failure. Psychosom Med 2013;75:632-639.
152. Hanon O, Vidal JS, de Groote P, Galinier M, Isnard R, Logeart D, Komajda M. Prevalence of memory disorders in ambulatory patients aged ≥70 years with chronic heart failure (from the EFICARE study). Am J Cardiol 2014;113:1205-1210.
153. Zuccala G, Pedone C, Cesari M, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003;115:97-103.
154. Hawkins LA, Kilian S, Firek A, Kashner TM, Firek CJ, Silvet H. Cognitive impairment and medication adherence in outpatients with heart failure. Heart Lung 2012;41:572-582.
155. Kraigher-Krainer E, Lyass A, Massaro JM, et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: The Framingham Heart Study. Eur J Heart Fail 2013;15:742-746.
156. Alosco ML, Spitxnagel MB, Cohen R, et al. Decreases in daily physical activity predict acute decline in attention and executive function in heart failure. J Card Fail 2015;21:339-346.
157. Alosco ML, et al. Cognitive dysfunction mediates the effects of poor physical fitness on decreased functional independence in heart failure. Geriatr Gerontol Int 2015;15:174-181.
158. Alosco ML, Spitznagel MB, Sweet LH, Josephson R, Hughes J, Gunstad J. Decreased physical activity predicts cognitive dysfunction and reduced cerebral blood flow in heart failure. J Neurol Sci 2014;339:169-175.
159. Alosco ML, Spitznagel MB, Cohen R, et al. Cardiac rehabilitation is associated with lasting improvements in cognitive function in older adults with heart failure. Acta Cardiol 2014;69:407-414.
160. Freimark D, Shechter M, Schwamenthal E, et al. Improved exercise tolerance and cardiac function in severe chronic heart failure patients undergoing a supervised exercise program. Int J Cardiol 2007;116:309-314.
161. Tanne D, Freimark D, Poreh A, et al. Cognitive functions in severe congestive heart failure before and after an exercise training program. Int J Cardiol 2005;103:145-149.
162. Alosco ML, Spitznagel MB, Cohen R, Sweet LH, Josephson R, Hughes J, Gunstad J. Decreases in body mass index after cardiac rehabilitation predict improved cognitive function in older adults with heart failure. J Am Geriatr Soc 2014;62:2215-2216.
163. Kindermann I, Fischer D, Karbach J, et al. Cognitive function in patients with decompensated heart failure: The Cognitive Impairment in Heart Failure (CogImpair-HF) study. Eur J Heart Fail 2012;14:404-413.
164. Alosco ML, Spitznagel MB, Cohen R, et al. Better adherence to treatment recommendations in heart failure predicts improved cognitive function at a one-year follow-up. J Clin Exp Neuropsychol 2014;36:956-966.
165. Duncker D, Friedel K, König T, et al. Cardiac resynchronization therapy improves psycho-cognitive performance in patients with heart failure. Europace 2015; pii: euv005.
166. Konstam V, Moser DK, De Jong MJ. Depression and anxiety in heart failure. J Card Fail 2005;11:455-463.
167. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527.
168. Morgan AL, Masoudi FA, Havranek EP, et al. Difficulty taking medications, depression, and health status in heart failure patients. J Card Fail 2006;12:54.
169. Lesman-Leegte I, van Veldhuisen DJ, Hillege HL, Moser D, Sanderman R, Jaarsma T. Depressive symptoms and outcomes in patients with heart failure: Data from the COACH study. Eur J Heart Fail 2009;11:1202.
170. Jiang W, Kuchibhatla M, Clary GL, et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007;154:102.
171. O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008;168:2232.
172. Riegel B, Moser DK, Anker SD, et al. American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Nutrition, Physical Activity, and Metabolism, American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: Promoting self-care in persons with heart failure: A scientific statement from the American Heart Association. Circulation 2009;120:1141.
173. Moudgil R, Haddad H. Depression in heart failure. Curr Opin Cadiol 2013;28:249-258.
174. Jiang W, Oken H, Fiuzat M, et al. Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. J Cardiovasc Transl Res 2012;5:92-99.
175. Löwe B, Kroenke K, Gräfe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res 2005;58:163.
176. Milani RV, Lavie CJ, Mehra MR, Ventura HO. Impact of exercise training and depression on survival in heart failure due to coronary heart disease. Am J Cardiol 2011;107:64-68.
177. Tousoulis D, Antonopoulos AS, Antoniades C, et al. Role of depression in heart failure-choosing the right antidepressive treatment. Int J Cardiol 2010;140:12-18.
178. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.
179. Fosbol EL, Gislason GH, Poulsen HE, et al. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of antidepressants and depend on the type of antidepressants used. Circ Heart Fail 2009;2:582-590.
180. Jiang W, Krishnan R, Kuchibhatla M, et al. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol 2011;107:545-551.
181. Jimenez JA, Redwine LL, Rutledge TR, et al. Depression ratings and antidepressant use among outpatient heart failure patients: Implications for the screening and treatment of depression. Int J Psychiatry Med 2012;44:315-334.
182. Chung ML, Dekker RL, Lennie TA, Moser DK. Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain. Heart Lung 2013;42:85-91.
183. Zhang JX, Rathouz PJ, Chin MH. Comorbidity and the concentration of healthcare expenditures in older patients with heart failure. J Am Geriatr Soc 2003;51:476-482.
184. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141.
185. ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC. Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimers Dement 2009;5:93-104.
186. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res 2009;2:310-321.
187. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305.
188. Feldman M, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTiernan C. The role of tumour necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-544.
189. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594.
190. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123.
191. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133.
192. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005;95:17C-23C; discussion 38C-40C.
193. Rahman I, Bellavia A, Wolk A. Relationship between physical activity and heart failure risk in women. Circ Heart Fail 2014;7:877-881.
194. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009;119:44-52.
195. Andersen K, Mariosa D, Adami HO, et al. Dose-response relationship of total and leisure time physical activity to risk of heart failure: A prospective cohort study. Circ Heart Fail 2014;7:701-708.
196. Patel K, Sui X, Zhang Y, et al. Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events. Int J Cardiol 2013;168:1905-1909.
197. Young DR, Reynolds K, Sidell M, et al. Effects of physical activity and sedentary time on the risk of heart failure. Circ Heart Fail 2014;7:21-27.
198. Conraads VM, Spruit MA, Braunschweig F, et al. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail 2014;7:279-287.
199. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-1450.
200. Vegh EM, Kandala J, Orencole M, et al. Device-measured physical activity versus six-minute walk test as a predictor of reverse remodeling and outcome after cardiac resynchronization therapy for heart failure. Am J Cardiol 2014;113:1523-1528.
201. Albert NM, Forney J, Slifcak E, Sorrell J. Understanding physical activity and exercise behaviors in patients with heart failure. Heart Lung 2015;44:2-8.
202. Nieuwenhuis MM, Jaarsma T, vanVeldhuisen DJ, Postmus D, der van Wal MH. Long-term compliance with nonpharmacologic treatment of patients with heart failure. Am J Cardiol 2012;110:392-397.
203. Ades PA, Keteyian SJ, Balady GJ, Houston-Miller N, Kitzman DW, Mancini DM, Rich MW. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail 2013;1:540-547.
204. Davidson PM, Cockburn J, Newton PJ, Webster JK, Betihavas V, Howes L, Owensby DO. Can a heart failure-specific cardiac rehabilitation program decrease hospitalizations and improve outcomes in high-risk patients? Eur J Cardiovasc Prev Rehabil 2010;17:393-402.
205. Wu JR, Lennie TA, Dekker RL, Biddle MJ, Moser DK. Medication adherence, depressive symptoms, and cardiac event-free survival in patients with heart failure. J Card Fail 2013;19:317-324.
206. van der Wal MH, Jaarsma T, Moser DK, van Gilst WH, van Veldhuisen DJ. Unravelling the mechanisms for heart failure patients' beliefs about compliance. Heart Lung 2007;36:253-261.
207. van der Wal MH, Jaarsma T, Moser DK, Veeger NJ, van Gilst WH, van Veldhuisen DJ. Compliance in heart failure patients: The importance of knowledge and beliefs. Eur Heart J 2006;27:434-440.
208. Boyne JJ, Vrijhoef HJ, Spreeuwenberg M, De Weerd G, Kragten J, Gorgels AP; TEHAF investigators. Effects of tailored telemonitoring on heart failure patients' knowledge, self-care, self-efficacy and adherence: A randomized controlled trial. Eur J Cardiovasc Nurs 2014;13:243-252.
209. Gjesing A, Schou M, Torp-Pedersen C. Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail 2013;15:671-678.
210. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm 2014;20:741-755.
211. Granger BB, Ekman I, Hernandez AF, et al. Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. Am Heart J 2015;169:539-548.
212. Yip VL, Pirmohamed M. Expanding role of pharmacogenomics in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2013;13:151-162.
213. Mestroni L, Taylor MR. Pharmacogenomics, personalized medicine, and heart failure. Discov Med 2011;11:551-561.
214. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-1195.